Trial NCT04422561
Publication Shouman W, J Clin Diagnostic Res, 2021 ()
Funding: No specific funding (No external funding was provided.)
Conflict of interest:
| Methods | |
| RCT Blinding: | |
| Location :
Multicenter / Egypt Follow-up duration (days): 14 | |
| Inclusion criteria | Asymptomatic household close contacts to confirmed RT-PCR COVID-19 index case; age equal to or more than 16 years; signed informed consent. |
| Exclusion criteria | Any contact developed symptoms or diagnosed as COVID-19 before enrollment; index case; failure to follow-up contacts for 14 days; failure to document the index case when there was more than one case in a family; refuse to participate and receive the drug; pregnancy; lactation; known hypersensitivity to ivermectin. |
| Interventions | |
| Treatment
Ivermectin (*) Duration : 3 days |
|
| Control
Standard care Definition of Standard care: * Duration : 2 weeks | |
| Participants | |
| Randomized 340 participants (n1=228 / n2= 112) | |
| Characteristics of participants N=340 Mean age : 39.1 156 males | |
| Primary outcome | |
| In the register Development of Symptoms (Fever, Cough, Sore Throat, Myalgia, Diarrhea, Shortness of Breath) [Time Frame: within 14 days after enrollment] | |
| In the report | |
| Documents available |
Protocol Yes. In English Statistical plan Yes Data-sharing stated NR |
| Risk of bias Overall The overall risk of bias reported in the table corresponds to the highest risk of bias for the outcomes assessed for the systematic review |
High |
| General comment | In addition to the published article, the trial registry and study protocol were used in data extraction and assessment of risk of bias. The trial was retrospectively registered. The trial registry lists COVID-19 by swab testing as a secondary outcome; however, this was not assessable in the report |